# A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia

> **NCT07205315** · EARLY_PHASE1 · RECRUITING · sponsor: **Grit Biotechnology** · enrollment: 28 (estimated)

## Conditions studied

- B-cell Acute Lymphoblastic Leukemia (B-ALL)
- Chronic Lymphocytic Leukemia (CLL)
- B-cell Non-Hodgkin's Lymphoma (B-NHL)
- Autoimmune Hemolytic Anemia (AIHA)

## Interventions

- **BIOLOGICAL:** GT801 Injection

## Key facts

- **NCT ID:** NCT07205315
- **Lead sponsor:** Grit Biotechnology
- **Sponsor class:** INDUSTRY
- **Phase:** EARLY_PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2025-09-26
- **Primary completion:** 2027-11-30
- **Final completion:** 2028-08-31
- **Target enrollment:** 28 (ESTIMATED)
- **Last updated:** 2026-04-23

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT07205315

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT07205315, "A Clinical Study Evaluating the Safety and Efficacy of GT801 Injection in Adult Patients With Relapsed/Refractory CD19-positive B-cell Hematologic Malignancies and Autoimmune Hemolytic Anemia". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT07205315. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*